Loading…
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $594M | $40M | $-56M | $38M | -3.2% | 3.6% | -66.2% |
| 2024 | $573M | $51M | $-165M | $12M | -9.3% | 4.0% | 1026.7% |
| 2023 | $551M | $29M | $-15M | $-34M | -0.6% | -0.7% | -100.7% |
| 2022 | $555M | $30M | $2.1B | $-543M | 63.4% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 555.50 | 551.49 | 573.45 | 593.82 |
| Cost Of Revenue | - | 299.91 | 312.28 | 318.83 | 323.54 |
| Gross Profit | - | 255.58 | 239.21 | 254.62 | 270.28 |
| Operating Expense | - | 279.01 | 295.88 | 294.48 | 291.95 |
| Operating Income | - | -23.42 | -56.67 | -39.86 | -21.67 |
| EBITDA | - | 30.28 | 28.92 | 50.88 | 39.54 |
| EBIT | - | -23.42 | -56.67 | -39.86 | -21.67 |
| Pretax Income | - | -9.94 | -20 | -19.12 | -7.14 |
| Tax Provision | - | 1.35 | -11.96 | 5.24 | -31.60 |
| Net Income | - | 2,132.86 | -14.64 | -164.90 | -55.76 |
| Net Income Common Stockholders | - | 2,132.86 | -14.64 | -164.90 | -55.76 |
| Total Expenses | - | 578.92 | 608.16 | 613.31 | 615.49 |
| Interest Expense | 2.04 | 4.59 | 0 | - | - |
| Interest Income | - | 15.70 | 43.54 | 32.89 | 18.78 |
| Research And Development | - | 27.54 | 32.14 | 31.52 | 30.39 |
| Selling General And Administration | - | 251.46 | 263.74 | 262.96 | 261.56 |
| Normalized EBITDA | - | 31.59 | 33.49 | 62.31 | 44.71 |
| Normalized Income | - | -10.25 | -4.42 | -15.34 | 28.54 |
| Market Cap | 1,193.45 | 1,193.45 | 1,193.45 | 1,193.45 | 1,193.45 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Azenta, Inc.this co. | AZTA | - | -21.40 | 0.69 | -3.2% | 24.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 |
| - |
| - |
| - |
| - |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |